Search Results Label

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.us/expertise/influenza

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic

https://www.seqirus.us/news/first-shipment-2021-22

Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.seqirus.us/products

Data now available on the first study to demonstrate the safety, immunogenicity and efficacy profile of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine

https://www.seqirus.us/news/study-simultaneous-admin-flu-covid

New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

https://www.seqirus.us/news/new-seqirus-data-published-in-vaccines-highlight-effectiveness

Company announces the publication of new real-world evidence on effectiveness of the MF59® adjuvanted, trivalent influenza vaccine (aTIV).

https://www.seqirus.us/news/new-rwe-flu-65-and-older

New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age

https://www.seqirus.us/news/data-supports-cell-based-flu-vaccine-in-children

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-late-breaking-data-at-idweek-2020

Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-expanded-age-indication